Key result
Primary percutaneous coronary intervention (PCI) provides benefits over thrombolytic therapy for STEMI, including reduced stroke and reinfarction, and improved survival.
Primary PCI is an effective treatment strategy for acute STEMI, offering benefits over thrombolytic therapy including reduced stroke and reinfarction rates.
ver the past decade, primary percutaneous coronary intervention (PCI) has emerged as an effective treatment strategy for acute ST-segment-elevation myocardial infarction (STEMI).Compared with thrombolytic therapy, the benefits of primary PCI include a reduction in the frequency of total stroke and hemorrhagic stroke, a reduction in the frequency of reinfarction, and an increase in the frequency of infarct-related artery patency, resulting in improved in-hospital and long-term survival.1 In addition, the availability of primary PCI provides a valid alternative for patients who have contraindications to thrombolytic therapy.
No takes yet. Share an insight, caveat, or question.
Moscucci et al. (2006) conducted a review in acute ST-segment-elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) vs. Thrombolytic therapy was evaluated. Primary percutaneous coronary intervention (PCI) provides benefits over thrombolytic therapy for STEMI, including reduced stroke and reinfarction, and improved survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: